The Comprehensive Cancer Center of Wake Forest University (CCCWFU) serves a large region in western North Carolina and contiguous regions in six adjoining states. In the last grant period, overall peer-reviewed cancer funding increased from $26 to $31 million (direct) and NCI funding increased from $12.2 to $17.7 million. Our NCI funding has increased 3.5 fold since 2000. Notable achievements include: Interdisciplinary and transdisciplinary interactions: Interprogrammatic and intraprogrammatic publications comprise 22% and 37% of publications in the Cellular Damage and Defense Program (CDD), 24% and 21% of those in the Cell Growth and Survival Program (COS), 22% and 40% in the Cancer Prevention and Control Program (CPC), and 22% and 22% of publications in the Clinical Research Program (CRP). Further, in 67%) of the peer-reviewed research grants in Summary II, CCCWFU principal investigators collaborate with other Cancer Center members as co-investigators or consultants These collaborative efforts are at highest levels since our Cancer Center began collecting these metrics. Innovative translational investigations: From our own preclinical science, we developed a portfolio of therapeutic and imaging clinical investigations. We also initiated nationally prominent programs in prostate cancer genetics, and, using our NCI-funded CCOP research base, led large-scale clinical trials in symptom management. Quality scientific contributions: Whether measured by high impact publications, NCI funding, or indisputably important contributions to cancer science and cancer care, CCCWFU investigators made important contributions to the national cancer effort. Support is requested for Cancer Center Support Grant for Years 37 through 41. The Center has four Programs: Cell Growth and Survival, Cellular Damage and Defense, Clinical Research, and Cancer Prevention and Control. Support is also requested for 9 shared resources: Bioanalytical Laboratory, Biostatistics, Cell and Viral Vector Core Laboratory, Cellular Imaging, Clinical Research Management, Crystallography and Computational Biosciences, Flow Cytometry, Microarray, and Tumor Tissue. For the next funding cycle, we have carefully crafted a strategic plan to reduce the burden of cancer in our region and in the nation.

Public Health Relevance

The Center serves a geographically contiguous, primarily rural area that spans seven states. In this region, the CCCWFU is the primary tertiary center for cancer care. The region has complex racial and ethnic populations that have traditionally not had access to state-of-the-art cancer prevention and treatment. The CCCWFU will not only continue to develop new areas of cancer treatment and prevention, but assure that our region has access to these advances.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA012197-37
Application #
8214195
Study Section
Subcommittee G - Education (NCI)
Program Officer
Ptak, Krzysztof
Project Start
1997-02-01
Project End
2017-01-31
Budget Start
2012-04-01
Budget End
2013-01-31
Support Year
37
Fiscal Year
2012
Total Cost
$1,318,600
Indirect Cost
$427,130
Name
Wake Forest University Health Sciences
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
937727907
City
Winston-Salem
State
NC
Country
United States
Zip Code
27157
Yang, M; Forbes, M E; Bitting, R L et al. (2018) Incorporating blood-based liquid biopsy information into cancer staging: time for a TNMB system? Ann Oncol 29:311-323
Godwin, Ryan C; Gmeiner, William H; Salsbury Jr, Freddie R (2018) All-atom molecular dynamics comparison of disease-associated zinc fingers. J Biomol Struct Dyn 36:2581-2594
Votanopoulos, Konstantinos Ioannis; Bartlett, David; Moran, Brendan et al. (2018) PCI is Not Predictive of Survival After Complete CRS/HIPEC in Peritoneal Dissemination from High-Grade Appendiceal Primaries. Ann Surg Oncol 25:674-678
Lamar, Zanetta S; Dothard, Andrew; Kennedy, LeAnne et al. (2018) Hyperglycemia during first-line R-CHOP or dose adjusted R-EPOCH chemotherapy for non-Hodgkin lymphoma is prevalent and associated with chemotherapy alteration - a retrospective study. Leuk Lymphoma 59:1871-1877
Melvin, Ryan L; Xiao, Jiajie; Berenhaut, Kenneth S et al. (2018) Using correlated motions to determine sufficient sampling times for molecular dynamics. Phys Rev E 98:023307
Bhatt, Nikunj B; Pandya, Darpan N; Dezarn, William A et al. (2018) Practical Guidelines for Cerenkov Luminescence Imaging with Clinically Relevant Isotopes. Methods Mol Biol 1790:197-208
Gesell, Sabina B; Golden, Shannon L; Limkakeng Jr, Alexander T et al. (2018) Implementation of the HEART Pathway: Using the Consolidated Framework for Implementation Research. Crit Pathw Cardiol 17:191-200
Mao, Chengqiong; Qu, Ping; Miley, Michael J et al. (2018) P-glycoprotein targeted photodynamic therapy of chemoresistant tumors using recombinant Fab fragment conjugates. Biomater Sci 6:3063-3074
Bhatt, Nikunj B; Pandya, Darpan N; Rideout-Danner, Stephanie et al. (2018) A comprehensively revised strategy that improves the specific activity and long-term stability of clinically relevant 89Zr-immuno-PET agents. Dalton Trans 47:13214-13221
Andrews, Rachel N; Caudell, David L; Metheny-Barlow, Linda J et al. (2018) Fibronectin Produced by Cerebral Endothelial and Vascular Smooth Muscle Cells Contributes to Perivascular Extracellular Matrix in Late-Delayed Radiation-Induced Brain Injury. Radiat Res 190:361-373

Showing the most recent 10 out of 548 publications